Related Experiment Video

Updated: Aug 19, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial

Hendrik Bonnemeier1, Jasmin Ortak, Ralph Tölg

  • 1Medizinische Kinik II, Universität zu Lübeck, Lübeck, Germany. bonnemei@medinf.mu-luebeck.de

Pacing and Clinical Electrophysiology : PACE
|February 3, 2005
PubMed

Insights

Carvedilol, unlike metoprolol, significantly improved cardiac electrical stability after primary percutaneous coronary intervention for acute myocardial infarction. This suggests carvedilol offers greater benefits in managing heart rhythm during this critical period.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Beta-adrenergic blockers are crucial for antiarrhythmic effects during myocardial ischemia and reperfusion.
  • Alpha-1 adrenoceptor blockade may further enhance ventricular repolarization dynamics in acute myocardial infarction (AMI).

Purpose of the Study:

  • To compare the effects of carvedilol and metoprolol on ventricular repolarization dynamicity after primary percutaneous coronary intervention (PCI) in patients with AMI.
  • To assess the impact of alpha-1 adrenoceptor blockade on cardiac electrical stability post-PCI.

Main Methods:

  • A prospective study randomized 100 AMI patients undergoing primary PCI to receive either metoprolol or carvedilol.
  • 24-hour ambulatory electrocardiograms were recorded, and QT/RR slopes were analyzed before and after reperfusion.
  • Linear regression analysis of QT/RR slopes was used to evaluate repolarization dynamicity.

Main Results:

  • No significant differences in baseline characteristics, RR-intervals, or QT-intervals were observed between the metoprolol and carvedilol groups.
  • Before PCI, QT/RR slopes were similar in both groups.
  • After PCI, carvedilol treatment was associated with a significant decrease in QT/RR slopes, indicating improved cardiac electrical stability, whereas metoprolol showed only a trend towards lower slopes.

Conclusions:

  • Carvedilol, due to its alpha-1 adrenoceptor blockade, confers greater cardiac electrical stability compared to metoprolol in patients undergoing primary PCI for AMI.
  • These findings suggest carvedilol may be a superior therapeutic option for managing ventricular repolarization dynamics in the acute phase of myocardial infarction.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...